ERBB2 and gastric cancer: For curing patients with HER2-positive carcinoma, especially breast and gastric cancer, DS-8201a is a newly developed ADC, having combination of the HER2-targeted antibody and a topoisomerase I inhibitor, with great potency [23, 27, 33].